Pulike secures new veterinary drug registration for Furorelan Solution

Pulike Biological Engineering Co., Ltd. and its subsidiary, Luoyang Huizhong Veterinary Pharmaceutical Co., Ltd., have obtained a new veterinary drug registration certificate for "Furorelan Solution." This approval, announced by the Ministry of Agriculture and Rural Affairs on October 11, 2025, follows a joint application and designates the product as a Class II new veterinary drug. Furorelan Solution is indicated for the treatment of flea and tick infestations in cats, including as part of a treatment plan for flea allergy dermatitis (FAD).

The new drug is administered externally, with dosages ranging from 0.4ml (containing 0.1125g furorelan) for cats weighing 1.2kg to 2.8kg, and 0.89ml (containing 0.25g furorelan) for cats weighing 2.8kg to 6.25kg, to be applied every 12 weeks. Furorelan Solution offers rapid and sustained efficacy for up to 12 weeks against fleas and ticks, preventing flea egg production and killing hard tick species.

This achievement underscores Pulike Biological Engineering's commitment to technological innovation and R&D investment. The company anticipates that this new product will significantly boost its market competitiveness and drive performance growth in the pet segment. The product still requires an approval number from the Ministry of Agriculture and Rural Affairs before commercial launch.